首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   90035篇
  免费   5658篇
  国内免费   48篇
林业   3780篇
农学   3494篇
基础科学   634篇
  11351篇
综合类   13557篇
农作物   3395篇
水产渔业   5000篇
畜牧兽医   47701篇
园艺   1174篇
植物保护   5655篇
  2020年   756篇
  2019年   975篇
  2018年   1609篇
  2017年   1862篇
  2016年   1682篇
  2015年   1426篇
  2014年   1745篇
  2013年   3752篇
  2012年   2959篇
  2011年   3621篇
  2010年   2366篇
  2009年   2345篇
  2008年   3497篇
  2007年   3216篇
  2006年   3152篇
  2005年   2680篇
  2004年   2580篇
  2003年   2595篇
  2002年   2377篇
  2001年   3392篇
  2000年   3308篇
  1999年   2555篇
  1998年   989篇
  1997年   1054篇
  1996年   885篇
  1995年   1023篇
  1994年   896篇
  1993年   896篇
  1992年   1846篇
  1991年   1921篇
  1990年   1856篇
  1989年   1859篇
  1988年   1608篇
  1987年   1595篇
  1986年   1629篇
  1985年   1526篇
  1984年   1225篇
  1983年   1033篇
  1982年   713篇
  1979年   1060篇
  1978年   816篇
  1975年   815篇
  1974年   897篇
  1973年   865篇
  1972年   805篇
  1971年   796篇
  1970年   801篇
  1969年   780篇
  1968年   708篇
  1967年   735篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
921.
922.
923.
924.
925.
926.
927.
928.
929.

Background

Transitional cell carcinoma is the most common bladder cancer of dogs. Cisplatin combined with piroxicam provides superior response rates, but unacceptable rates of nephrotoxicity. Tavocept is a chemoprotectant that has mitigated cisplatin toxicity and decreased the required infusion/diuresis volume in clinical trials in humans.

Hypothesis/Objectives

We hypothesized that Tavocept would decrease diuresis volume and time and facilitate safe administration of a cisplatin/piroxicam protocol to dogs with bladder cancer. Secondary objectives were to compare response rate and survival times to an historical comparator group treated without Tavocept.

Animals

Fourteen client‐owned dogs were prospectively enrolled.

Methods

Tumor volume was measured by computed tomography at days 0, 42, and 84. Dogs received combination Tavocept/cisplatin with a shortened diuresis protocol. A total of 4 doses was planned, with concurrent administration of piroxicam. Serial biochemical analyses were evaluated for azotemia.

Results

A 90‐minute infusion/diuresis time was used for all dogs. Three dogs (21%) had concurrent increases in serum creatinine (>2.0 mg/dL) and BUN (>42 mg/dL) concentrations; 2 of these dogs were isosthenuric. This frequency of nephrotoxicity is significantly less (P = 0.0406) than that of an historical control group treated without Tavocept. Overall response rate was 27%. Median survival time was comparable to historical controls (253 vs. 246 days).

Conclusions and Clinical Importance

Tavocept decreased the required diuresis time with cisplatin from > 6 hours to 90 minutes, while also decreasing occurrence of azotemia. Survival time was comparable, but the response rate was inferior to an historical comparator group. Further evaluation in other tumors susceptible to platinum agents is warranted.  相似文献   
930.

Background

Chiari‐like malformation (CM) and syringomyelia (SM) cause a pain syndrome in Cavalier King Charles spaniels (CKCS). Clinical signs are not consistently apparent on neurologic examination, and owner reporting of signs provides vital clinical history. However, owner questionnaires for this disease are not well developed.

Objectives

To develop a tool to capture owner‐reported clinical signs for use in clinical trials and to compare owner‐reported signs with the presence of pain on neurologic examination and SM on magnetic resonance imaging (MRI).

Animals

Fifty client‐owned CKCS.

Methods

Owners completed a questionnaire and pain/scratch map. Each dog underwent a neurologic examination and craniocervical magnetic resonance imaging (MRI). Questionnaire responses were developed into scores, area of shading for pain/scratch maps was measured, and consistency of responses between these tools was assessed. Owner‐reported findings were compared with neurologic examination findings and presence and severity of SM on MRI.

Results

Thirty‐three dogs were symptomatic and 17 asymptomatic; 30 had SM. The most common sign of pain was crying out when lifted (n = 11). Extent of shaded areas on maps positively correlated with questionnaire scores for pain (r2 = 0.213, = 0.006) and scratch (r2 = 0.104, = 0.089). Owner‐reported findings were not significantly associated with presence or severity of SM or neurologic examination findings. Owner‐reported lateralization of signs was significantly associated with SM lateralization (< 0.0001).

Conclusions

The questionnaire and maps may be useful for clinical trials. Lack of association of owner‐reported signs with SM highlights our lack of understanding of the pathophysiology of pain in this disease.  相似文献   
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号